NASDAQ$GBIO
Generation Bio Co · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Generation Bio reported fourth quarter and full year 2023 financial results and business highlights.
Generation Bio is focusing on advancing its cell-targeted lipid nanoparticle and immune-quiet DNA platforms, with a focus on in vivo programs for sickle cell disease, beta-thalassemia, and hemophilia A. The company's cash balance is expected to fund operations into the second half of 2027.
- Developing ctLNP for in vivo T cell and hematopoietic stem cell programs.
- Developing iqDNA for programs in hepatocytes and other cell types.
- Cash, cash equivalents and marketable securities were $264.4 million as of December 31, 2023.
- The company continues to believe that its cash, cash equivalents and marketable securities will fund its operating expenditures and capital expenditure requirements into the second half of 2027.
Headline financials
Revenue & EPS history
Generation Bio · Revenue · Quarterly
$2.88M
Revenue by segment
Generation Bio · $2.15M total across 1 segment · Q3 2023
- Collaboration revenue$2.15M—100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q4 2023
+3.8%
Avg return
Earnings day
+5.9%
Avg return
5 days after
+8.6%
Avg return
30 days after
43%
10 / 23 earnings
Positive
+61.7%
Q2 2025
Best reaction
-19.7%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -3.3% | +11.0% | +2.7% | |
| Q2 2025 | +61.7% | +62.0% | +46.9% | |
| Q1 2025 | +4.5% | +0.4% | +4.0% | |
| Q4 2024 | -3.7% | -14.3% | -9.5% | |
| Q3 2024 | +8.7% | -0.5% | -40.8% | |
| Q2 2024 | -2.0% | -3.7% | -10.2% | |
| Q1 2024 | +18.4% | +16.4% | +1.9% | |
| Q4 2023 | +3.1% | +11.5% | +39.4% | |
| Q3 2023 | -1.7% | +7.7% | +46.2% | |
| Q2 2023 | -5.3% | -7.0% | +6.8% | |
| Q1 2023 | -5.0% | -2.7% | +0.4% | |
| Q4 2022 | -8.4% | -10.0% | +15.5% | |
| Q3 2022 | +12.2% | — | — | |
| Q2 2022 | +7.7% | — | — | |
| Q1 2022 | -19.7% | — | — | |
| Q4 2021 | +21.1% | — | — | |
| Q3 2021 | -1.5% | — | — | |
| Q2 2021 | -6.2% | — | — | |
| Q1 2021 | +0.3% | — | — | |
| Q4 2020 | -0.9% | — | — | |
| Q3 2020 | +8.5% | — | — | |
| Q4 2019 | -0.5% | — | — | |
| Q2 2020 | -0.5% | — | — | |
| Q1 2020 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro